The U.S. health regulator revised on Jan. 24 the emergency use authorizations for COVID-19 antibody treatments from Regeneron and Eli Lilly to limit their use, as the drugs are unlikely to work against the Omicron coronavirus variant.
If you are not happy with the results below please do another search
50 search results for:
A New York judge struck down the state’s mask mandate on Jan. 24, one week before it was due to expire, ruling the governor overstepped her authority in imposing a rule that needed to have been passed by the state legislature.
The U.S. Food and Drug Administration granted Emergency Use Authorization for Mammoth Biosciences Inc.’s DETECTR BOOST SARS-CoV-2 Reagent Kit, a first of its kind high-throughput solution that combines the power of CRISPR with laboratory automation for SARS-CoV-2 testing.
The Omicron variant can survive longer than earlier versions of the coronavirus on plastic surfaces and human skin, Japanese researchers found in laboratory tests. Additionally, new research shows users of rapid antigen tests to detect COVID-19 should swab their nostrils as directed by the manufacturer and not swab the throat or cheek instead.
A third booster dose of a COVID-19 vaccine made by AstraZeneca, Pfizer-BioNTech or Johnson & Johnson increases antibody levels significantly in those who have previously received two doses of Sinovac’s CoronaVac shot, a study has found.
TScan Therapeutics secured clearance from the U.S. Food and Drug Administration for the company’s investigational new drug application to assess TSC-100 in treating patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation (HCT).
The head of the World Health Organization (WHO) warned on Jan. 24 that it was dangerous to assume the Omicron variant would herald the end of COVID-19’s acutest phase, exhorting nations to stay focused to beat the pandemic.
At least 1 in 5 Americans have been infected with COVID-19. In other news, the U.S. Food and Drug Administration approved Gilead Sciences’ supplemental New Drug Application for Veklury (remdesivir) for adults and adolescents with COVID-19 who are not hospitalized but are at high risk of progression to severe COVID-19, hospitalization or death.
The U.S. Food and Drug Administration issued a Complete Response Letter to Merck & Co. for the company’s New Drug Application for gefapixant for refractory chronic cough or unexplained chronic cough.
A fourth dose of COVID-19 vaccine given to people over 60 years in Israel made them three times more resistant to serious illness than thrice-vaccinated people in the same age group, Israel’s Health Ministry said on January 23.